A Phase 3 interventional study of Ensure, Abbott Nutrition and standard hospital diet in Heart Diseases, sponsored by Meshalkin Research Institute of Pathology of Circulation. Terminated at 2 sites in Russian Federation. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-03-24.
Sponsored by Meshalkin Research Institute of Pathology of Circulation · Phase 3, Interventional, and Treatment
The purpose of this study is to determine whether postoperative nutritional support improves postoperative outcomes in cardiac patients with malnutrition .
3,639 studies on the registry are indexed under Heart Diseases; 461 are open to participants now.
This study's enrollment of 21 is below the median of 100 across 1,778 interventional studies indexed under Heart Diseases.
Browse Heart Diseases studies →Meshalkin Research Institute of Pathology of Circulation is the lead sponsor of 114 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
postoperative nutritional supplements in addition to standard hospital diet
Dietary Supplement: Ensure, Abbott Nutrition
patients receiving standard hospital diet
Other: standard hospital diet
Enteral feeding Ensure, Abbott Nutrition 400 ml per day for seven postoperative days
standard hospital diet
Mortality
Time frame: 1 month
Postoperative complications
Cardiac arrhythmia, infectious complications.
Time frame: 1 month
Total lymphocyte count
Time frame: before operation, 7, 14, 21 postoperative days
Serum albumin
Time frame: Before operation, 7, 14, 21 postoperaitve days
Serum prealbumin
Time frame: Before operation, 7, 14, 21 postoperaitve days
Retinol-binding protein
Time frame: Before operation, 7, 14, 21 postoperaitve days
This study is terminated, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Meshalkin Research Institute of Pathology of Circulation